ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1932

Evaluating a Potential Cause of Excess Lung Cancer Mortality in RA: An Analysis of Chest CT Imaging Frequency in RA

Rebecca Brooks1, Sara Achenbach2, Vanessa Kronzer1, Bryant England3, Emily Leasure1, Elena myasoedova1, John Davis1 and Cynthia Crowson4, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, 3University of Nebraska Medical Center, Omaha, NE, 4Mayo Clinic, Stewartvillle, MN

Meeting: ACR Convergence 2025

Keywords: Cohort Study, Health Services Research, prevention, rheumatoid arthritis, Smoking

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (1914–1935) Health Services Research Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Recent studies have demonstrated that patients with RA are at an increased risk for the development of lung cancer and lung cancer related death. However, the cause for the increased risks has not been established. Although previous studies have investigated the delay of other age recommended cancer screenings, few studies have investigated lung cancer screening in RA patients with a smoking history. Therefore, we evaluated the cumulative incidence of chest CT imaging in RA patients with either a current or former smoking history between 50-80 years old.

Methods: We performed a retrospective cohort study of patients with incident RA in a geographically defined area who fulfilled either the 1987 ACR or 2010 ACR/EULAR classification criteria between 2010 and 2019. Non-RA comparators of similar age, sex and county were randomly selected. The analyses included RA and non-RA patients who were between the ages of 50 and 80 years old and were either former or current smokers. Patients with a prior history of lung cancer were excluded from analyses. Chest CT imaging was defined as completed if it was performed by the end of the study period, emigration out of the geographical area, or death. Aalen-Johansen methods determined the cumulative incidence of chest CT imaging in both cohorts, accounting for the competing risk of death. Cox proportional hazard models adjusted for age, sex, index year, and education were utilized to compare the rates of chest CT imaging.

Results: This study included 407 patients with RA and 360 non-RA comparators. The patients with RA had a mean age of 63 years, 57% being female, and 52% having education beyond high school. During follow-up, >50% of the RA patients had chest CT imaging (55.8% [50.7-61.5]) compared to the non-RA cohort with < 40% (37.8% [32.3-44.2]) (Figure 1). After adjusting for age, sex, index year, and education, the patients with RA were 90% more likely to have chest CT imaging compared to the non-RA cohort (aHR 1.90 [1.51-2.39]. The increased likelihood of chest CT imaging persisted when examining former (aHR 1.95 [1.48-2.57]) and current (aHR 1.88 [1.23-2.89]) smokers separately.

Conclusion: RA was associated with an >85% increase in chest CT imaging after adjusting for potential confounders in this analysis of former and current smokers. These findings suggest that the increased risk of lung cancer related death in RA patients is not due to a decrease in chest CT imaging leading to a delay in the diagnosis of lung cancer. The increased incidence of chest CT imaging in the RA cohort could partially be explained by the increased risk of interstitial lung disease in those with RA, prompting more frequent evaluation of respiratory symptoms with chest CT imaging. Therefore, further studies investigating adherence to lung cancer screening guidelines, the effect of changes in lung cancer screening guidelines, and the impact of pack years are necessary to fully understand the impact of lung cancer screening on the RA population.

Supporting image 1Figure 1. Cumulative Incidence of Chest CT Imaging in RA versus non-RA comparators


Disclosures: R. Brooks: None; S. Achenbach: None; V. Kronzer: None; B. England: Boehringer-Ingelheim, 2, 5; E. Leasure: None; E. myasoedova: None; J. Davis: Pfizer, 5, Remission Medical, 1, 9, 10, Rheumasense, 1, 9, 10; C. Crowson: None.

To cite this abstract in AMA style:

Brooks R, Achenbach S, Kronzer V, England B, Leasure E, myasoedova E, Davis J, Crowson C. Evaluating a Potential Cause of Excess Lung Cancer Mortality in RA: An Analysis of Chest CT Imaging Frequency in RA [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/evaluating-a-potential-cause-of-excess-lung-cancer-mortality-in-ra-an-analysis-of-chest-ct-imaging-frequency-in-ra/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluating-a-potential-cause-of-excess-lung-cancer-mortality-in-ra-an-analysis-of-chest-ct-imaging-frequency-in-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology